Skip to main content

Column Group L P's Form 4 filing

NGM Biopharmaceuticals Inc (NGM) · filed May 13, 2022

Accession no.
0000899243-22-018031
Filed
May 13, 2022, 5:32 PM ET
Trade date
May 11-12, 2022
Filing delay
2 days
Rule 10b5-1 plan
Not on the form (before 2023)

This filing lists 8 non-derivative transactions. Open-market purchases total $1.90M. It was filed 2 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Column Group L PCIK 0001347769Director, 10% Owner
Column Group GP, LPCIK 000161462710% Owner
Column Group III-A, LPCIK 000166808510% Owner
Column Group III, LPCIK 000166815910% Owner
Column Group IV-A, LPCIK 000179635310% Owner
Column Group IV, LPCIK 000179635410% Owner
Column Group IV GP, LPCIK 000179635610% Owner
TCG IV GP, LLCCIK 000179635910% Owner

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
May 11, 2022Common StockPPurchaseAcquired+77,866$11.23F1+$874,108.141,010,189IndirectDuplicate filing
May 11, 2022Common StockPPurchaseAcquired+2,657$11.23F1+$29,826.9534,475IndirectDuplicate filing
May 11, 2022Common StockPPurchaseAcquired+2,564$11.85F4+$30,376.481,012,753IndirectDuplicate filing
May 11, 2022Common StockPPurchaseAcquired+88$11.85F4+$1,042.5634,563IndirectDuplicate filing
May 12, 2022Common StockPPurchaseAcquired+79,945$11.62F5+$929,048.841,092,698IndirectDuplicate filing
May 12, 2022Common StockPPurchaseAcquired+2,728$11.62F5+$31,702.3637,291IndirectDuplicate filing
May 12, 2022Common StockPPurchaseAcquired+485$11.81F6+$5,725.761,093,183IndirectDuplicate filing
May 12, 2022Common StockPPurchaseAcquired+17$11.81F6+$200.737,308IndirectDuplicate filing

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F1

The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $10.745 to $11.74, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of securities purchased at each separate price within the ranges set forth in this footnote (1) to this Form 4.

Referenced by the price of 2 transactions in Table I.

F4

The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $11.76 to $11.99, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of securities purchased at each separate price within the ranges set forth in this footnote (4) to this Form 4.

Referenced by the price of 2 transactions in Table I.

F5

The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $10.73 to $11.72, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of securities purchased at each separate price within the ranges set forth in this footnote (5) to this Form 4.

Referenced by the price of 2 transactions in Table I.

F6

The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $11.74 to $11.88, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of securities purchased at each separate price within the ranges set forth in this footnote (6) to this Form 4.

Referenced by the price of 2 transactions in Table I.

Remarks

Due to SEC restrictions on the number of reporting owners, this is Form 2 of 2.

Read the full filing on SEC EDGAR (opens in a new tab)